The invention discloses a pantoprazole sodium compound, which is crystal. In X-ray powder diffraction pattern obtained through Cu-Kalpha ray measurement, the characteristic peaks of the pantoprazole sodium compound are shown in positions where 2theta is 12.5, 12.6, 13.2, 16.2 and 17.3. The pantoprazole sodium compound can be used together with multiple freeze-drying supporting agents, the prepared freeze-dried powder injection has the advantages of good redissolution, good transparency after redissolution, low impurity content and the like; and moreover, the use amount of the freeze-drying supporting agent is lower, thus saving the pharmaceutical cost and improving the stability of a drug preparation. The invention also discloses a pharmaceutical composition. The pharmaceutical composition comprises a pharmaceutical active ingredient and pharmaceutical auxiliary materials, wherein the pharmaceutical active ingredient is the pantoprazole sodium compound. The stability of the pharmaceutical composition is obviously superior to that of commercial products, and especially, the stability duration of the pharmaceutical composition after being matched with common infusion fluid is prolonged, thus facilitating the clinical application.